Resistance to antiviral drugs in influenza viruses can emerge following medication or may result from natural variation. Two classes of anti-influenza drugs targeting either the M2 protein (amantadine and rimantadine) or neuraminidase (NA) (oseltamivir and zanamivir), are currently licensed. These drugs are expected to be important in controlling early stages of a potential pandemic. In the present study, we describe how a pyrosequencing method can be used to rapidly detect established molecular markers of resistance to M2 blockers and to NA inhibitors in A(H5N1) viruses.
Introduction
cell culture (16, 18, 27) . In recent years, a significant increase of adamantane resistance was also reported among some groups of influenza A(H5N1) viruses (11, 24, 25) . This necessitates a close monitoring of adamantane resistance among diverse groups of rapidly evolving influenza A(H5N1) viruses, including viruses circulating in avian populations.
Emergence and spread of adamantane resistant virus variants in three antigenic subtypes H3N2, H1N1, and H5N1 of influenza A viruses influenced the decision to stockpile NAIs to be used for mitigation of pandemic influenza. Emergence of oseltamivir-resistant viruses in treated individuals have been seen at a low frequency (~1%) in the adult population (44) and more often (up to 30%) in young children (26) and immunocompromised patients. Nevertheless, until recently, resistance to this class of drugs has been very low (<0.5%) in community isolates (23, 25, 32, 33, 36) . During the season 2007-2008, however, a significant rise in resistance to oseltamivir was detected among seasonal influenza A(H1N1) viruses recovered from untreated individuals of different ages and in distant geographic locations (28, 41). The emerged oseltamivirresistant H1N1 viruses retain sensitivity to zanamivir. These recent findings emphasized the need for close monitoring of NAI resistance among seasonal influenza viruses as well as among highly virulent H5N1 viruses. In contrast to adamantanes, molecular markers of resistance to NAIs are not yet well characterized. Moreover, resistance to NAIs is drugspecific and NA type/subtype-specific, reviewed by (19) . Of note, H5N1 viruses of different genetic groups (clades/subclades) exhibit substantial variance in their NA sequences and susceptibility to NAIs (10, 32, 47) . For these reasons, the NA activity inhibition assay is currently used as the primary assay for monitoring resistance to NAIs (21, 35, 41, 43, 45) . This method requires virus propagation in cell culture prior to testing
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on October 16, 2017 by guest http://aac.asm.org/ Downloaded from and needs to be complemented by sequence analysis of the NA to confirm known or to detect novel markers of NAI-resistance. Oseltamivir-resistant H5N1 viruses with amino acid changes at two residues H274Y and N294S have emerged in humans during oseltamivir treatment (15, 29) . The impact of natural drift mutations in the NA on the drug susceptibility of H5N1 viruses has been reported (13, 32 , 37) but is not readily predicted. Moreover, when existing NAIs were designed, crystal structures of the influenza N1 subtype enzyme, including that of H5N1 viruses were not available. Recent crystal structure data and conformational studies of influenza N1 enzyme showed that replacements at residues outside of the conserved active site (e.g. residues Q136 and K150 in the 150-loop of the NA molecule) could affect binding of the existing drugs to the NA by interfering with their induced fit into the active site (10, 30, 38, 47) . Although the exact mechanisms by which some changes (e.g., residues V116, I117, Q136, K150, and I222) in the N1 enzyme affect susceptibility to a particular NAI are not well understood, there is a need to monitor their presence in multiple and evolving clades of H5N1 viruses.
The ability to rapidly detect markers of antiviral drug resistance is a valuable tool in the view of influenza pandemic preparedness. Especially desirable are rapid, highthroughput methods which are sensitive and minimize handling of live viruses.
Pyrosequencing has been proven to provide such an option for the detection of resistance to adamantanes in seasonal influenza A viruses and more recently this method was expanded for detection of resistance to NAIs in seasonal and H5N1 viruses (16, 18, 27) . In the present study, we enhanced the existing pyrosequencing approach by expanding the number of targeted markers (from 2 to 7) in the NA of H5N1 viruses and also provided validation of pyrosequencing assays of both M2 and N1NA by testing H5N1 viruses from a variety of genetic groups (clades/subclades). Based on results of the enzyme inhibition assays (2, 5, 25, 27, 32) , replacements at some of the targeted residues in the NA (e.g., V116, I117, Q136, K150, and I222) have previously been linked to reduced drug-susceptibility in avian and human viruses carrying N1. However, some of them may yet be proven to have little relevance for clinical resistance. Nevertheless, the pyrosequencing assay developed here provides a robust tool for detection of influenza virus variants including those directly from clinical specimens and thus would be instrumental in identifying new mechanisms of resistance to the newer NAI class of antiinfluenza drugs. (Table 1 ) .

Material and Methods
Viruses
Throughout the manuscript, amino acid residues in the N1 NA are shown according to the universal N2 subtype numbering. BioEdit software (version 5.0.6, North Carolina State University), the N1 consensus sequence was generated. Similarly, a consensus sequence was generated based on alignment of their M gene sequences. These consensus sequences were used to design the pyro RT-PCR and sequencing primers using Pyrosequencing Assay Design software (Biotage). In several instances, primers were modified to accommodate degenerate nucleotides. The primers were synthesized at the CDC Biotechnology Core facility (Table 2 ).
Pyrosequencing
Resistance to adamantanes is associated with mutations occurring at one or more of the residues 26, 27, 30, 31 and 34 (7, 11) in the M2 protein. The RT-PCR primers were designed to amplify a region encompassing these amino acids (from nt 739 to nt 1027).
RT-PCR and pyrosequencing. Viral RNAs were extracted from viral supernatants in lysis buffer. RT-PCR amplifications were performed using one-step RT-PCR system (Qiagen, Valencia, CA). Primers were used at 20µM in a standard 25µl reaction mixture and amplification for 45 cycles. Biotinylated amplicons were purified and the pyrosequencing reactions carried out as previously described in (7) using the PSQ In addition, the sensitivity of the pyrosequencing assay was assessed using RNA extracted from serially 10-fold diluted virus stocks. One hundred microliters from each virus dilution was added to equal volume of lysis buffer in BSL3+ containment. RNAs were used to perform the RT-PCR amplifications as described above and pyrosequencing that could be used to generate pyrograms of high-quality resolution using the designed pyrosequencing primers. The RNAs from the highest dilution of the virus stock were also subjected to real-time RT-PCR analysis. 
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Results
Detection of molecular markers of A(H5N1) virus resistance to M2 blockers.
Because of the conserved nature of influenza A M2 sequences, it was possible to use the same set of primers to detect adamantane resistance-conferring mutations in two antigenic subtypes of seasonal influenza, H1N1 and H3N2 (7). Here, we assessed the ability of the same primers to detect adamantane resistance in H5N1 subtype. We found that overall the same assay protocol was suitable for the majority of the H5N1 viruses.
However, when the modified forward primer (Table 2) 
Discussion
Monitoring of drug resistance among H5N1 viruses is a challenging task due to their rapid evolution and the need for BSL-3-enhanced containment for work with live viruses. In this study, we demonstrate the development of a rapid and high-throughput pyrosequencing method that could be utilized for the reliable detection of known molecular markers of influenza viruses resistant to neuraminidase inhibitors (NAIs) or adamantanes from a variety of influenza A H5N1 viruses. It is worth noting that because our assay was designed to encompass all 7 currently known markers associated with drug resistance in the influenza NA, it differs markedly from other described methods (18, 27) , which were designed to only target 1 or 2 markers. Moreover, recent work elucidating N1 NA structure have shown that previous work on the design of neuraminidase inhibitors may not have been optimal for targeting the N1 subtype of the NA and natural resistance to such designed drugs can be conferred by changes in residues outside of the immediate N1 active site (10, 30, 38, 47, 49) . Indeed, drug susceptibility testing using the NA inhibition assay showed that naturally occurring amino acid replacements outside of the NA active site (e.g. V116, I117 ) can alter the susceptibility of avian H5N1 viruses to oseltamivir and/or zanamivir (25, 32). Although evaluation of resistance from a variety of clinical specimens (16, 18, 27 ).
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In the present study, we conducted assessment of the pyrosequencing assay using two approaches. The viral RNA was extracted from the virus stocks and then serially diluted RNA preparations were subjected to RT-PCR and pyrosequencing. Alternatively, the serial dilutions were made from the virus stocks and then viral RNA was extracted and used for RT-PCR amplifications followed by pyrosequencing. The second approach may provide a better estimation of the assay sensitivity. In both instances, RNAs were used to determine Ct values of the highest dilutions that generated good quality 
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